Neusignal Therapeutics, Inc.
PrivateLast Round
Series B
Jun 30, 2026
Total Funding Raised
$48.97M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Neusignal Therapeutics, Inc. is a biotechnology company that develops small-molecule oral drugs for the treatment of dementia and other central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neusignal Therapeutics, Inc. Comparables
Compare Neusignal Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Asceneuron | 84% | |
| AriBio | 83% | |
| NeuroTherapia, Inc. | 81% | |
Neusignal Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 30, 2026 | ||||
| Series A | Jan 31, 2025 | ||||
| Seed | Mar 1, 2024 | ||||
| Seed | Sep 1, 2022 |
Neusignal Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| THE GOGIN CAPITAL Co., Ltd. | Series B |
| Angel Bridge | Series B |
| Keio Innovation Initiative | Series B, Seed, Series A |
| Mizuho Capital | Seed, Series A |
| DCI Partners | Series B |
| 日本ベンチャーキャピタル株式会社 | Series B, Series A |
| Nissay Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 30, 2026
$33M round led by Angel Bridge and DCI Partners.
- Jan 31, 2025
$7.34M round with SMBC Venture Capital and others.
Neusignal Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neusignal Therapeutics, Inc.'s valuation, stock price, and market status.